logo
Government's new health strategy ‘no more than hiding the crisps', Tories say

Government's new health strategy ‘no more than hiding the crisps', Tories say

Yahooa day ago

The Government's 10-year health strategy to tackle demand on the NHS centres on 'hiding the crisps', a shadow minister has said.
Under new proposals, retailers could be made to set targets to increase their sales of less fattening products.
Shadow work and pensions secretary Helen Whately said setting mandatory targets for supermarkets was 'nanny state'.
'They had 14 years in opposition to think about what they wanted to do about the NHS, they've had a year in government, and the number one thing in it seems to be hide the crisps,' she told Sky News' Sunday Morning With Trevor Phillips.
'It's obviously the nanny state, but it's also not what people want for the NHS.
'People want to hear how they're going to get to see their GP.
'Telling people what to buy, I think, is not up to government. I believe in personal responsibility.'
Health Secretary Wes Streeting told the same programme the Government will work with supermarkets to help 'nudge people in the right direction'.
'By taking the approach we're taking with supermarkets, they will decide through the combination of where they put their products, how they do price promotions, the reformulation, what products they choose to put on the shelves,' he said.
'They will work with us to make sure that we nudge people in the right direction without any of us even noticing, in the same way that we've nudged the country in the other direction since the 1990s.'
Rejecting suggestions that the idea was too controlling, he said it was different to 'traditional nanny statism, where we regulate more heavily on price, on marketing, on what's sold'.
Labour's 10-year health plan is set to be published next week.
Other changes could include money for hospitals being linked to patient ratings.
According to the Times, part of the proposals will see patients contacted a few weeks after their hospital treatment for feedback.
Based on their responses, money could be diverted to a local 'improvement fund'.
Another proposal could see NHS users awarded points for upping their step count and eating healthily.
Points can then be traded for vouchers, with discounts at supermarkets and coffee shops, according to The Sun.
Hundreds of bodies responsible for overseeing and running parts of the NHS in England are likely to be scrapped as part of the changes.
Mr Streeting has said the current system is too complex and needs reform.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Affidea Group selects b-rayZ as its preferred AI partner in breast imaging, marking strategic collaboration
Affidea Group selects b-rayZ as its preferred AI partner in breast imaging, marking strategic collaboration

Yahoo

timean hour ago

  • Yahoo

Affidea Group selects b-rayZ as its preferred AI partner in breast imaging, marking strategic collaboration

THE HAGUE, The Netherlands, June 30, 2025 (GLOBE NEWSWIRE) -- In a strategic move to improve patient outcomes in breast cancer, Affidea, a leading pan-European provider of community-based polyclinics, specialist services and advanced diagnostics, is proud to announce that it has selected b-rayZ, a leader in AI-powered breast imaging solutions, as its preferred AI partner for breast imaging. Breast cancer diagnostics often face fragmentation, with critical information scattered across different modalities and specialists. This can slow down decision-making and delay life-saving treatments. b-rayZ's AI-powered platform is designed to eliminate these gaps, ensuring a seamless diagnostic pathway that enhances both clinical precision and therapeutic options for women. By choosing b-rayZ as its AI partner, Affidea is taking a decisive step towards making precision medicine a reality, one diagnosis at a time. The b-rayZ solution is already in use in Affidea Switzerland, at Affidea's Centre of Excellence in Breast Cancer, Brust Zentrum Zurich, as well as at Affidea Givision, Site Hôpital Daler. The technology has also been successfully implemented across other markets such as Affidea Lithuania and Affidea Spain, with further expansions planned in other Affidea countries offering breast imaging services. These early installations reflect the growing momentum and confidence in b-rayZ's ability to standardise and elevate diagnostic quality across diverse clinical environments. By implementing this innovative AI solution, Affidea is reinforcing its commitment to early detection and improved outcomes in breast cancer across Europe. Affidea has also joined b-rayZ as a strategic investor in their Series A extension equity funding round. This investment marks a significant milestone in b-rayZ's journey and validates their vision and growth strategy. The partnership strengthens b-rayZ's position in the industry and opens up valuable collaboration opportunities to accelerate product development, expand into new markets, and enhance customer offerings. Cristina Rossi, CEO and founder of b-rayZ, stated: 'At b-rayZ, we are deeply committed to preserving women's health. Every woman's journey through breast cancer diagnosis is unique, and our AI solutions are designed to provide the highest level of diagnostic accuracy and efficiency, tailored to each one's needs. Being selected by Affidea as their preferred AI partner is a testament to our shared vision of transforming breast cancer diagnostics. Affidea's investment in our Series A extension further validates this alignment and fuels our ambition to scale. Through this strategic partnership, we are combining our technological expertise with Affidea's extensive clinical network to ensure that women across Europe receive faster, more precise, and more personalised breast imaging solutions.' Dr Charles Niehaus, Deputy CEO of Affidea, highlighted the broader strategic impact of the partnership: 'This collaboration with b-rayZ represents more than just the adoption of AI. It is a strategic alliance aimed at redefining breast cancer diagnostics. Together, we plan to deepen our collaboration to further develop the AI solutions, to empower radiologists, optimise clinical workflows, and improve patient care. This partnership – both strategic and financial – positions us in the right direction to accelerate innovation across our network. By integrating AI across our network, we are ensuring that women across Europe receive the most accurate and timely diagnoses possible, tailored to them, reinforcing our mission to set new standards in patient care.' Dr Alessandro Roncacci, SVP and Chief Medical Officer at Affidea, added: 'Breast imaging is a highly specialised field that requires precision, experience, and the ability to interpret complex data. AI-powered solutions, like those developed by b-rayZ, are revolutionising breast cancer diagnostics by augmenting radiologists' expertise and ensuring greater consistency in detection. Through this partnership, we are integrating AI to enhance our sub-specialty breast imaging, improving diagnostic accuracy, and optimising personalised screening pathways. This marks a significant step forward in delivering earlier diagnoses, reducing variability in interpretations, and ultimately ensuring the best possible clinical outcomes for women across Europe.' About Affidea GroupAffidea ( is a leading pan-European provider of specialist healthcare services, including cancer care, community-based polyclinics and advanced diagnostic imaging. Founded in 1991, the company operates over 410 centres across 15 countries, with more than 14 million patient visits every year. Due to its track record for patient safety, the company has become the most awarded diagnostic imaging provider in Europe by the European Society of Radiology (ESR), as over 90% of its centres are recognised on the Eurosafe Wall of Stars by the ESR. Affidea is majority-owned by Groupe Bruxelles Lambert (GBL), a leading investment holding company, focused on long-term value-creation with a stable and supportive family shareholder base. About b-rayZThe b-rayZ AI solution ( is part of an ever-growing multi-modality platform fully dedicated to breast cancer diagnostics. b-rayZ supports women throughout their diagnostic journey with a tailored ecosystem of solutions driven by clinical needs. With cutting-edge AI technology and years of clinical experience in breast imaging, b-rayZ offers a comprehensive yet easy-to-use solution that provides a comprehensive set of industry-leading AI modules. All of these modules are designed to meet the needs of medical professionals and support the daily work of both medical radiology assistants, radiologists and hospital managers. Media Contacts For b-rayZKevin OlbrichMarketing Manager b-rayZ For Affidea GroupOana DumitroiuSenior Vice-President Marketing & A photo accompanying this announcement is available at

Ovation Fertility AI Research Abstract Selected for Presentation at ESHRE 2025
Ovation Fertility AI Research Abstract Selected for Presentation at ESHRE 2025

Associated Press

timean hour ago

  • Associated Press

Ovation Fertility AI Research Abstract Selected for Presentation at ESHRE 2025

PARIS, FRANCE, June 30, 2025 / / -- Ovation® Fertility's groundbreaking research on the use of artificial intelligence in embryo selection has been accepted for presentation at the renowned European Society of Human Reproduction and Embryology (ESHRE) 2025 Annual Meeting. The study, entitled 'Retrospective comparison of deep learning versus logistic regression for selecting the best embryo for transfer,' was featured in a poster presentation at this year's 41st annual conference in Strombeek-Bever, Belgium. Co-authored by Michael Fanton of California-based Alife Health and US Fertility & Ovation Fertility 's Vice President of Scientific Advancement Matthew (Tex) VerMilyea, PhD, HCLD/CC (ABB), the study sought to understand how the performance of a deep learning model compares to a logistic regression model for embryo ranking using prospectively collected embryo images. 'Ovation Fertility has been studying the use of artificial intelligence in embryo selection for several years, and this most recent study helps us fine-tune the use of these tools to improve pregnancy rates for patients using IVF,' VerMilyea says. 'This study tells us that both deep learning and logistic regression models show promise for identifying the 'most likely to succeed' embryo produced in an IVF cycle. This is good news for patients because AI has the potential to increase the chances the rate of successful pregnancy in single embryo transfers.' The study evaluated 4,543 images and morphology grades of individual embryos from 870 patients at two fertility clinics in the United States. The images were collected prospectively using an embryo image capture software (Alife Embryo Assist) between January and December 2024. With 90% of the embryos already genetically tested, the study's authors used both deep learning and logistic regression models to rank each patient's embryos, testing each model's success in selecting the best embryo for transfer. The study found that the top-ranked deep learning embryo was transferred in 45% of cohorts, with the top-ranked logistic regression embryo transferred in 76% of cohorts. Transferring the top-ranked embryo by deep learning was associated with an 8.9% higher pregnancy rate. Transferring the top-ranked embryo by logistic regression was associated with a 4.1% higher pregnancy rate. The simplicity and interpretability of the logistic regression may allow for faster adoption and clinical trust, while deep learning may further enhance success rates. About Ovation Fertility Ovation Fertility, part of the US Fertility network, is a leading national consortium of IVF laboratories dedicated to advancing reproductive care. Working closely with affiliated physician practices, Ovation leverages cutting-edge, evidence-based fertility treatments to provide hopeful parents with the highest chances of success. Ovation offers a comprehensive range of services, including frozen donor and surrogacy services and secure storage solutions for frozen biomaterials. Together, Ovation and its partners are committed to setting new standards in reproductive medicine. Learn more at Press Team Ovation Fertility +1 424-239-1088 email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Portable devices 'life-changing' for patients
Portable devices 'life-changing' for patients

Yahoo

time3 hours ago

  • Yahoo

Portable devices 'life-changing' for patients

A cancer charity has donated equipment worth almost £10,000 to help palliative care patients enjoy "everyday family life". Easington's East End Cancer Relief Charity (EECR) has provided eight "life-changing" ambulatory syringe drivers to Castle Hill Hospital in Cottingham, East Yorkshire. The small and portable devices are used to continually administer a patient's medication over a set period, the charity said. Locally, the devices have recently been used by a woman attending her sister's wedding and by a teenager attending a music festival, a spokesperson added. The charity, which is already planning further fundraising events, raised a total of £9,600 through activities, including a bike ride, craft fairs, raffles and a country and western night. Charity trustee Andrea Robinson said: "We are immensely proud to be able to provide support in this way and it was fantastic to hear first-hand from the nursing staff the difference the syringe drivers make to patients' lives. "I would like to take this opportunity to say a special thank you to everyone who has helped at our events and have donated either money or goods to contribute to the funds raised," she added. EECR was originally set up in the late 1970s and over the years has raised more than £190,000. It became a registered charity in May 2023. Listen to highlights from Hull and East Yorkshire on BBC Sounds, watch the latest episode of Look North or tell us about a story you think we should be covering here. Children's cancer wig charity plans expansion Cancer patients 'priced out' of holidays, charity warns Double trek made cancer survivor 'feel alive' Hull University Teaching Hospitals NHS Trust

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store